No headlines found.
Globe Newswire (Tue, 15-Oct 8:00 AM ET)
Rob Bazemore Appointed to the Board of Directors of Akari Therapeutics
Globe Newswire (Tue, 17-Sep 8:00 AM ET)
Akari Therapeutics Reports Second Quarter 2024 Financial Results and Recent Highlights
Globe Newswire (Mon, 19-Aug 4:15 PM ET)
Globe Newswire (Mon, 19-Aug 8:00 AM ET)
Akari Therapeutics PLC is a clinical stage biopharmaceutical company. It is focused on developing therapies for autoimmune and inflammatory diseases involving the complement component 5 (C5) and leukotriene B4 (LTB4) pathways. The company's pipelines include HSCT-TMA and Geographic Atrophy (GA).
Akari Therapeutics PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AKTX.
As of October 23, 2024, AKTX stock price climbed to $2.21 with 1,940 million shares trading.
AKTX has a market cap of $26.84 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, AKTX traded as high as $35.40 and as low as $1.08.
AKTX has underperformed the market in the last year with a price return of -35.0% while the SPY ETF gained +38.9%. AKTX has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -43.0% and -27.8%, respectively, while the SPY returned +4.5% and +0.8%, respectively.
AKTX support price is $1.91 and resistance is $2.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AKTX shares will trade within this expected range on the day.